Zogenix price target raised to $66 from $56 at Empire

Empire analyst Dr. Cathy Reese raised Buy rated Zogenix’s price target to $66 from $56 citing a reduction in clinical development risk following Fintepla’s second confirmatory Phase III study. Reese said this was the final large Fintepla clinical hurdle that needed to be cleared so Zogenix could file its U.S. and E.U. submissions for this drug to be considered as a therapy for Dravet syndrome patients.

https://bit.ly/2Ou8GNB